Drug maker Lupin on Thursday said it has received approval from the US health regulator to market a generic medication to treat certain eye conditions.
The company has received approval from the US Food and Drug Administration to market Etabonate Ophthalmic Suspension, the Mumbai-based drug maker said in a statement.
The company's product is the generic equivalent of Bausch & Lomb Inc's Lotemax ophthalmic suspension (0.5%), it added.
Loteprednol Etabonate ophthalmic suspension, 0.5%, is indicated for temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.
ADVERTISEMENT
As per the IQVIA MAT data, the product had estimated annual sales of USD 59 million in the US.
Add us to your Preferences
Set as your preferred source on Google
ADVERTISEMENT
RECOMMENDED FOR YOU
Ardee Engineering Gets SEBI Nod For Rs 580-Crore IPO
Aug 26, 2025
ITC Seeks CCI Nod To Acquire ABREL's Century Pulp Paper Business For Rs 3,498 Crore
Aug 26, 2025
Indian Company's Cookware Products Likely To Cause Lead Poisoning, USFDA Warns
Aug 18, 2025
Andhra Pradesh Secures $7.9 Billion Data Center Investments From Google, Sify
Jul 31, 2025
POPULAR
1
GST Reform: Opposition-Run States Support Rate Cuts, Seek Safeguards Against Revenue Loss
2
Reliance AGM 2025 Live Updates: Mukesh Ambani To Address Shareholders Today Amid Jio IPO Buzz
3
Stock Market LIVE: Nifty, Sensex Rangebound; Rupee Breaches 88 Against US Dollar
4
Nifty India Defence Down 21% From 52-Week High — What Lies Ahead For HAL, Bharat Dynamics And Others?
5